Factorial Modeling for Effective Suppression of Directional Noise

2017 ◽  
Author(s):  
Osamu Ichikawa ◽  
Takashi Fukuda ◽  
Gakuto Kurata ◽  
Steven J. Rennie
Keyword(s):  
Effective Suppression

scholarly journals Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Ryan Kolb ◽  
Umasankar De ◽  
Sajid Khan ◽  
Yuewan Luo ◽  
Myung-Chul Kim ◽  
...  
Keyword(s):  
T Cells ◽  
Regulatory T Cells ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Molecular Target ◽  
Therapeutic Strategies ◽  
Normal Tissues ◽  
Effective Suppression ◽  
Immunosuppressive Microenvironment ◽  
Cancer Immunotherapies

AbstractRegulatory T cells (Tregs) play an important role in maintaining immune homeostasis and, within tumors, their upregulation is common and promotes an immunosuppressive microenvironment. Therapeutic strategies that can eliminate Tregs in the tumor (i.e., therapies that do not run the risk of affecting normal tissues), are urgently needed for the development of cancer immunotherapies. Here we report our discovery of B-cell lymphoma extra-large (BCL-XL) as a potential molecular target of tumor-infiltrating (TI) Tregs. We show that pharmacological degradation of BCL-XL using a newly developed platelet-sparing BCL-XL Proteolysis-targeting chimera (PROTAC) induces the apoptosis of TI-Tregs and the activation of TI-CD8+ T cells. Moreover, these activities result in an effective suppression of syngeneic tumor growth in immunocompetent, but not in immunodeficient or CD8+ T cell-depleted mice. Notably, treatment with BCL-XL PROTAC does not cause detectable damage within several normal tissues or thrombocytopenia. These findings identify BCL-XL as a target in the elimination of TI-Tregs as a component of cancer immunotherapies, and that the BCL-XL-specific PROTAC has the potential to be developed as a therapeutic for cancer immunotherapy.

scholarly journals Effective Suppression of the Polysulfide Shuttle Effect in Lithium–Sulfur Batteries by Implementing rGO–PEDOT:PSS-Coated Separators via Air-Controlled Electrospray

ACS Omega ◽  
2018 ◽  
Vol 3 (12) ◽  
pp. 16465-16471 ◽  
Author(s):  
Jin Hong Lee ◽  
Jisoo Kang ◽  
Seung-Wan Kim ◽  
Willy Halim ◽  
Margaret W. Frey ◽  
...  
Keyword(s):  
Shuttle Effect ◽  
Effective Suppression ◽  
Lithium Sulfur Batteries ◽  
Lithium Sulfur ◽  
Polysulfide Shuttle

scholarly journals Effective suppression of nitric oxide production by HX106N through transcriptional control of heme oxygenase-1

2015 ◽  
Vol 240 (9) ◽  
pp. 1136-1146 ◽  
Author(s):  
Doo Suk Lee ◽  
Binna N. Kim ◽  
Seonung Lim ◽  
Junsub Lee ◽  
Jiyoung Kim ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Heme Oxygenase ◽  
Transcriptional Control ◽  
Heme Oxygenase 1 ◽  
Nitric Oxide Production ◽  
Oxide Production ◽  
Effective Suppression

Hydrophilic crosslinked-polymeric surface capable of effective suppression of protein adsorption

2016 ◽  
Vol 378 ◽  
pp. 467-472 ◽  
Author(s):  
Yuri Kamon ◽  
Naoko Inoue ◽  
Erika Mihara ◽  
Yukiya Kitayama ◽  
Tooru Ooya ◽  
...  
Keyword(s):  
Protein Adsorption ◽  
Polymeric Surface ◽  
Effective Suppression

Effective suppression of atrial fibrillation by the antihistaminic agent antazoline: First experimental insights into a novel antiarrhythmic agent

2017 ◽  
Vol 35 (2) ◽  
pp. e12244 ◽  
Author(s):  
Gerrit Frommeyer ◽  
Magdalena Sterneberg ◽  
Dirk G. Dechering ◽  
Sven Kaese ◽  
Nils Bögeholz ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Antiarrhythmic Agent ◽  
Effective Suppression ◽  
Antihistaminic Agent

scholarly journals Properties of the antigen-specific suppressive T-cell factor in the regulation of antibody response of the mouse. IV. Special subregion assignment of the gene(s) that codes for the suppressive T-cell factor in the H-2 histocompatibility complex.

1976 ◽  
Vol 144 (3) ◽  
pp. 713-725 ◽  
Author(s):  
T Tada ◽  
M Taniguchi ◽  
C S David
Keyword(s):  
T Cell ◽  
B Cells ◽  
Antibody Response ◽  
Gene Products ◽  
T Cell Factor ◽  
Recombinant Strains ◽  
Histocompatibility Complex ◽  
Effective Suppression ◽  
Absorption Studies ◽  
Lines Of Evidence

The locus of the gene that codes for the antigen-specific suppressive T-cell factor was determined to be in a new subregion "I-J" which locates between I-B and I-C subregions in the H-2 histocompatibility complex. This was shown by two different lines of evidence: (a) The absorbing capacity for the suppressive T-cell factor of several alloantisera against restricted I subregions did not correlate with their specificity for previously known Ia molecules which are coded for by genes in I-A and I-C subregions, but was associated with the specificity for the products of genes putatively present between I-B and I-C subregions. By the occurrence of special recombinant strains, i.e. B10.A(5R), B10.A(3R), B10.S(9R), and B10.HTT, which differ with respect to the I-J subregion, we were able to produce alloantisera which distinguish I-J subregion gene products. The absorption studies using these special alloantisera directed to I-J subregion clearly indicated that the suppressive T-cell factor is a product of I-J subregion gene(s), and that the molecule is distinct from known Ia molecules expressed on splenic B cells. (b) Taking advantage of the fact that there is a strict histocompatibility requirement for the effective suppression between the donor and recipient strains of the suppressive T-cell factor, we were able to determine the required identities of the genes in the H-2 complex existing among those present between I-B and I-C. Again, utilizing the T-cell factors obtained from special recombinant strains, i.e. B10.A(4R) and B10.A(5R), we were able to locate the gene that codes for the suppressive T-cell factor reactive only with relevant haplotype strains between I-B and I-C subregions. These results are most reasonably explained by the presence of a new subregion I-J which is specialized in coding for the suppressive T-cell factor as a different molecule from previously known Ia molecules.

Sign in / Sign up

Export Citation Format

Share Document